CF PharmTech (HKG:2652) raised HK$525.4 million in net proceeds from its initial public offering in Hong Kong.
The inhalation drug developer set the final offer price of its offering of 41,198,000 shares at HK$14.75 per share, according to a late Monday filing with the Hong Kong bourse.
The Hong Kong public offering was 6,697.80 times oversubscribed, and the company offered 4,120,000 shares, the same number of shares initially allotted.
The international offering was 12.74 times subscribed, with the final share allocation maintained at 37,078,000 shares.
CF PharmTech will make its trading debut on the bourse today, Oct. 8.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.